AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Traws Pharma, Inc. Director's Dealing 2018

Dec 15, 2018

35199_dirs_2018-12-14_8a558964-4fe7-4a0e-a6d3-ec939d8f3596.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2018-12-12

Reporting Person: OLER ABRAHAM N. (VP Corp Dev & Gen Counsel)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to purchase)	$4.34	2028-12-01	Common Stock (20000)		Direct

Footnotes

F1: These options vest over 4 years. 25% vests on 12/1/2019. The remaining 75% vests over the subsequent 3 years in 36 equal monthly installments.